MedPath

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Trifluridine/tipiracil hydrochloride (S 95005)
Drug: Oxaliplatin
Drug: Bevacizumab
Drug: Nivolumab
Registration Number
NCT02848443
Lead Sponsor
Institut de Recherches Internationales Servier
Brief Summary

The main purpose of this study is to assess the safety and tolerability and to determine the recommended phase 2 dose of S 95005 given in combination with oxaliplatin in patients with metastatic colorectal cancer.

Detailed Description

This is a one-arm study, which will be conducted in 2 parts:

* A dose-escalation part to determine the Maximum Tolerated Dose (MTD) of S 95005 in combination with oxaliplatin.

* An expansion part in patients treated at the recommended dose defined in the dose escalation part of this study to evaluate the safety, PK, and preliminary efficacy of S 95005 in combination with oxaliplatin and either bevacizumab or nivolumab.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • Age 18 years or older.
  • Histologically confirmed metastatic colorectal cancer pretreated by at least one line of standard chemotherapy.
  • Restaging scan within 28 days before the first study drug intake.
  • During the dose-escalation part, patient must have at least one evaluable or measurable metastatic lesion; and during the expansion part, patient must have at least one measurable metastatic lesion.
  • Life expectancy of more than 3 months.
  • Performance status Eastern Cooperative Oncology Group (ECOG): 0-1.
  • Adequate bone marrow, liver, and kidney function.
  • For patients who will receive bevacizumab: coagulation parameters in normal limit or in therapeutic limit for patients treated with anticoagulant.
  • For patients who will receive nivolumab: patients eligible for tumour biopsy and who agree to have two sequential biopsies during the study.
  • Women of childbearing potential must have a negative pregnancy test. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use highly effective birth control method. Women and female partners using hormonal contraceptive must also use a barrier method.
  • Capacity to take oral tablet(s) without difficulty.
  • Has provided written informed consent.
  • Is willing and able to comply with scheduled visits and study procedures.
Read More
Exclusion Criteria

  • Grade 2 or higher peripheral neuropathy.

  • During expansion part, patients who had recurrence during or within 6 months of completion of the adjuvant chemotherapy with oxaliplatin.

  • Patients with brain metastases or leptomeningeal metastasis.

  • Other malignancy within the last 3 years (except for basal cell carcinoma or a non-invasive/in situ cervical cancer)

  • Has had certain other recent treatment e.g. major surgery, field radiation, participation in another interventional study, within the specified time frames prior to study drug administration.

  • Certain serious illnesses or serious medical conditions

  • For patients who will receive bevacizumab: history of allergic reactions/hypersensitivity to bevacizumab, to any components used in the formulation, to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.

  • Grade 3 or higher hypersensitivity reaction to oxaliplatin or garde 1-2 hypersensitivity reaction to oxaliplatin not controlled with premedication.

  • Patient previously treated by S 95005 or history of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipient. Patient with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

  • Any condition that, in the judgment of the Investigator, may affect the patient's ability to understand and sign the informed consent and fully comply with all study procedure.

  • Pregnancy or breast feeding.

  • For patients planned to receive nivolumab:

    • Patients with active autoimmune disease or history of clinically severe autoimmune disease.
    • Patients with a condition requiring systemic treatment with either corticosteroids (> 20 mg daily prednisone equivalent) or other immunosuppressive medications within the specified time frames prior to first study drug intake.
    • Prior treatment with anti-PD-1, anti-PD-L1, anti-programmed cell death ligand-2, anti-CD137, anti-OX-40, anti-CD40, anti-cytotoxic T lymphocyte-associated antigen-4 antibodies (CTLA-4), or any other immune checkpoint inhibitors.
    • Prior events of immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis and renal dysfunction, immune-mediated rash, immune-mediated encephalitis.
    • Allergic reactions/hypersensitivity to nivolumab or any components used in its formulation or previous severe hypersensitivity reaction to treatment with another monoclonal antibody.
    • Has a known history of active tuberculosis (Bacillus Tuberculosis).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)Trifluridine/tipiracil hydrochloride (S 95005)-
S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)Bevacizumab-
S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)Oxaliplatin-
S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)Nivolumab-
Primary Outcome Measures
NameTimeMethod
Maximum Tolerated Dose (MTD) of S95005 when given in combination with oxaliplatinup to 4 weeks after the first treatment administration
Changes in standard hematology as a measure of safety and tolerability for S95005-oxaliplatinthrough study completion, an average of 9 months
Changes in vital signs as a measure of safety for S95005-oxaliplatinthrough study completion, an average of 9 months

Vital sign measurements will include temperature, systolic and diastolic blood pressure, heart rate, and respiratory rate.

Number of participants with adverse events as a measure of safety and tolerability for S95005-oxaliplatin.through study completion, an average of 9 months

Adverse event reporting will be graded following the National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03

Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatinthrough study completion, an average of 9 months
Dose Limiting Toxicity (DLT) of S95005 when given in combination with oxaliplatinup to 4 weeks after the first treatment administration
Changes in coagulation as a measure of safety and tolerability for S95005-oxaliplatinthrough study completion, an average of 9 months
Changes in urinalysis as a measure of safety and tolerability for S95005-oxaliplatinthrough study completion, an average of 9 months
Changes in biochemistry as a measure of safety and tolerability for S95005-oxaliplatinthrough study completion, an average of 9 months
Secondary Outcome Measures
NameTimeMethod
Changes in vital signs as a measure of safety for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months

Vital sign measurements will include temperature, systolic and diastolic blood pressure, heart rate, and respiratory rate.

Changes in urinalysis as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months
Antitumor activity assessed by RECIST (Response Evaluation Criteria in Solid Tumors) and CEA (Carcinoembryonic Antigen)through study completion, an average of 9 months
Changes in standard hematology as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months
PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumabup to 8 weeks after the first treatment administration

Tumour biopsy at baseline and at the end of Cycle 4

Number of participants with adverse events as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months

Adverse event reporting will be graded following the National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03

Changes in biochemistry as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months
Changes in coagulation as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab.through study completion, an average of 9 months
Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin + bevacizumab or nivolumab.through study completion, an average of 9 months

Trial Locations

Locations (24)

La Pitié Salpêtrière Centre Investigation clinique Paris Est

🇫🇷

Paris, France

Klinikum Wolfsburg Medizinische Klinik II

🇩🇪

Wolfsburg, Germany

Institut Gustave Roussy DITEP

🇫🇷

Villejuif, France

H. Valle de Hebrón - Servicio de Oncología - (VHIR)

🇪🇸

Barcelona, Spain

H. Uni. Madrid Sanchinarro - CIOCC Servicio de Oncología

🇪🇸

Madrid, Spain

Christie Hospital NHS Foundation Trust GI & Endocrine

🇬🇧

Manchester, United Kingdom

ICO Badalona. H. Germans Trials y Pujol - Servicio de Oncología médica

🇪🇸

Badalona, Spain

H. Clinico de Valencia INCLIVA - Departamento de Hematologia y Oncologia Medica 8ª planta

🇪🇸

Valencia, Spain

Universitätsklinikum Hamburg-Eppendorf II. Medizin. Klinik und Poliklinik (Onkologie, Hämatologie)

🇩🇪

Hamburg, Germany

Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie

🇦🇹

Wien, Austria

CHU de la Timone Hépato-Gastro-Entérologie - Oncology Digestive

🇫🇷

Marseille, France

Policlinico G.B. Rossi A.O.U.I. di Verona U.O.C. di Oncologia

🇮🇹

Verona, Italy

Centre Eugène Marquis Service d'Oncologie Médicale

🇫🇷

Rennes, France

Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly

🇭🇺

Budapest, Hungary

Semmelweis Egyetem I. sz. Belgyogyaszati Klinika - Klin. Farmakologiai Reszleg

🇭🇺

Budapest, Hungary

St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum Abteilung für Hämatologie und Onkologie

🇩🇪

Bochum, Germany

Universitätsklinikum Ulm Zentrum für Innere Medizin, Klinik für Innere Medizin I

🇩🇪

Ulm, Germany

Hôpital Saint-Antoine Service d'Oncologie Médicale

🇫🇷

Paris, France

Orszagos Onkologiai Intezet "B" Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O.

🇭🇺

Budapest, Hungary

Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III

🇩🇪

Munchen, Germany

ARNAS - Azienda Ospedaliera Garibaldi - Nesima Struttura Complessa di Oncologia Medica

🇮🇹

Catania, Italy

Ist.Scientifico Romagnolo per lo Studio e la Cura dei Tumori Department of Clinical Oncology

🇮🇹

Meldola, Italy

Hospital Unviersitario Gregorio Marañon - Servicio de Oncología Médica

🇪🇸

Madrid, Spain

H. Univ. Ramon y Cajal - Servicio de Oncología Medica

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy